As a result, the survival, proliferation, and glycolysis of pancreatic cancer cells can be dramatically decreased by inhibiting IL-6 and its related pathways, and the treatment resistance of pancreatic cancer cells can even be reduced [37]. Here, IL6 is linked to familial pancreatic carcinoma.